Stocks · News reference
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.09) by 7.34 percent. This is a 2.88 percent increase over losses of $(1.04) per share
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Entrada Therapeutics granted 61,365 RSUs and options to purchase 19,425 shares to eight newly-hired non-executive employees under its 2025 Inducement Equity Plan, effective September 1, 2026. The options have an exercise price of $7.07 per share, with vesting schedules spanning four years for options and multiple years for RSUs, contingent on continued employment.
Filed: 2026-08-05 AccNo: 0001689375-26-000052 Size: 243 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits